Related Experiment Video
Updated: Apr 3, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Comprehensive assessment of cancer missense mutation clustering in protein structures
Atanas Kamburov1, Michael S Lawrence2, Paz Polak1
1Department of Pathology and Cancer Center, Massachusetts General Hospital, Boston, MA 02114; Harvard Medical School, Boston, MA 02115; Broad Institute of MIT and Harvard, Cambridge, MA 02142;
Abstract:
Large-scale tumor sequencing projects enabled the identification of many new cancer gene candidates through computational approaches. Here, we describe a general method to detect cancer genes based on significant 3D clustering of mutations relative to the structure of the encoded protein products. The approach can also be used to search for proteins with an enrichment of mutations at binding interfaces with a protein, nucleic acid, or small molecule partner. We applied this approach to systematically analyze the PanCancer compendium of somatic mutations from 4,742 tumors relative to all known 3D structures of human proteins in the Protein Data Bank. We detected significant 3D clustering of missense mutations in several previously known oncoproteins including HRAS, EGFR, and PIK3CA. Although clustering of missense mutations is often regarded as a hallmark of oncoproteins, we observed that a number of tumor suppressors, including FBXW7, VHL, and STK11, also showed such clustering. Beside these known cases, we also identified significant 3D clustering of missense mutations in NUF2, which encodes a component of the kinetochore, that could affect chromosome segregation and lead to aneuploidy. Analysis of interaction interfaces revealed enrichment of mutations in the interfaces between FBXW7-CCNE1, HRAS-RASA1, CUL4B-CAND1, OGT-HCFC1, PPP2R1A-PPP2R5C/PPP2R2A, DICER1-Mg2+, MAX-DNA, SRSF2-RNA, and others. Together, our results indicate that systematic consideration of 3D structure can assist in the identification of cancer genes and in the understanding of the functional role of their mutations.
Insights
This study introduces a 3D structural method to identify cancer genes by analyzing mutation clustering. The approach reveals new insights into both known and potential cancer-driving genes and their functional roles.
Area of Science:
- Genomics
- Structural Biology
- Computational Biology
Background:
- Large-scale tumor sequencing generates numerous cancer gene candidates.
- Identifying functional cancer genes requires robust analytical methods.
- Understanding mutation impact necessitates considering protein structure.
Purpose of the Study:
- To develop and apply a general method for detecting cancer genes using 3D protein structure.
- To identify proteins with significant 3D clustering of mutations.
- To analyze mutation enrichment at protein interaction interfaces.
Main Methods:
- Utilized a computational approach analyzing mutation clustering relative to 3D protein structures.
- Applied the method to the PanCancer compendium of somatic mutations (4,742 tumors).
- Examined mutation distribution at binding interfaces with protein, nucleic acid, or small molecule partners.
Main Results:
- Detected significant 3D missense mutation clustering in known oncoproteins (HRAS, EGFR, PIK3CA) and tumor suppressors (FBXW7, VHL, STK11).
- Identified novel 3D mutation clustering in NUF2, a kinetochore component potentially affecting chromosome segregation.
- Revealed mutation enrichment at specific interaction interfaces, including FBXW7-CCNE1 and HRAS-RASA1.
Conclusions:
- Systematic consideration of 3D protein structure aids in identifying cancer genes.
- The method enhances understanding of the functional consequences of cancer mutations.
- Structural analysis provides a powerful framework for cancer gene discovery and characterization.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
04:56Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025